Cambridge Antibody Technology and Crucell settle patent dispute.

(From Chemical Business NewsBase - Press Release)

Cambridge Antibody Technology (CAT) and Crucell NV have agreed on terms whereby Crucell receives from CAT a worldwide licence with respect to all CAT's antibody phage display technology patents, both pending and granted. As a result of this agreement, all existing litigation between the two companies has been withdrawn. CAT obtains an option to develop certain antibodies, opening the way for further collaboration between the companies. Under the agreement CAT will receive an initial licence fee from Crucell. In return, Crucell, and its partners, will be free to develop and commercialize human antibody products against …